MGTA - Magenta Therapeutics GAAP EPS of -$0.27 beats by $0.03
- Magenta Therapeutics press release ( NASDAQ: MGTA ): Q3 GAAP EPS of -$0.27 beats by $0.03 .
- Cash, cash equivalents and marketable securities as of September 30, 2022, were $128.3 million, compared to $176.9 million as of December 31, 2021.
For further details see:
Magenta Therapeutics GAAP EPS of -$0.27 beats by $0.03